Short report

DOI: 10.4244/EIJ-D-18-00172

Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS stents for coronary bifurcation treatment: four-year results of the randomised POLBOS I and POLBOS II clinical trials

Robert J. Gil1,2, MD, PhD; Jacek Bil1, MD, PhD; Adam Kern3, MD, PhD; Luis A. Ingio Garcia4, MD; Radoslaw Formuszewicz5, MD; Slawomir Dobrzycki6, MD, PhD; Dobrin Vassilev7, MD, PhD; Agnieszka Segiet8, MSc, PhD

Introduction

The wide variation in bifurcation anatomy has generated ongoing research for stents designed specifically for coronary bifurcations; results to date have been unsatisfactory1,2. Earlier, we presented 12 months of pooled data from the POLBOS I and II trials (ClinicalTrials.gov Identifiers: NCT02192840, NCT02198300)3; the present study extends the follow-up to four years.

Methods

OUTCOME MEASURES

The primary endpoint was the cumulative rate of major adverse cardiovascular events (MACE) consisting of cardiac death, myocardial infarction (MI), and target lesion revascularisation (TLR) within 48 months. The secondary endpoints were defined in the primary publication3.

STATISTICAL ANALYSIS

Detailed methods have been described previously3. The significance level was set at 0.05. Statistical analyses were performed using R version 3.0.2 for Mac OS (R Foundation for Statistical Computing, Vienna, Austria).

Results

As reported earlier, our population of 445 patients (222 patients in the BiOSS® [Balton, Warsaw, Poland] group and 223 patients in the regular drug-eluting stent [rDES] group) was analysed3. There were no statistical differences between the BiOSS and rDES groups at 12 months in terms of MACE (BiOSS 12.6% vs rDES 13.5%, p=0.43), TLR (10.8% vs 8.1%, p=0.14), MI (1.8% vs 3.1%, p=0.68), or cardiac death (0% vs 2.2%, p=0.79). Similarly, no differences were observed after 2, 3, and 4 years of follow-up. At 48 months, the MACE rate was 19.8% in the BiOSS group and 18.8% in the rDES group (p=0.64), whereas TLR rates were 15.3% and 12.1%, respectively (p=0.34). The Kaplan-Meier curves for MACE and TLR for the BiOSS and rDES subgroups are shown in Figure 1. Further, to determine the prognostic factors for coronary bifurcation treatment, univariate and multivariate regression analyses were performed (Table 1).

Figure 1. Kaplan-Meier curves showing 48-month outcomes. Kaplan-Meier curves showing event-free survival in the whole population (BiOSS vs rDES) and in the second-generation rDES (BiOSS vs second-generation rDES) for MACE and TLR.

Discussion

The data obtained for the BiOSS and DES groups were comparable with those observed in the literature4,5. Also, the five-year outcomes from the LEADERS trial were as follows: MACE 35.3%, cardiac deaths 8.5%, MI 11.9%, and TLR 14.9%6. In regression analysis, we found that female sex and proximal optimisation technique (POT) decreased the chance of MACE, whereas MV predilatation, non-ST-elevation myocardial infarction (NSTEMI)/unstable angina (UA), true bifurcation, and diabetes treated with insulin increased the chance of MACE. These findings are similar to those of other studies7. For example, in the Milan and New-Tokyo (MITO) Registry, independent predictors of main branch in-stent restenosis (MB-ISR) were calcification (HR 2.284, p=0.016), true bifurcation (HR 2.331, p=0.024), and insulin-dependent diabetes (HR 2.259, p=0.048). Furthermore, POT (HR 0.548, p=0.077), full left main cover approach (HR 0.605, p=0.093), and greater minimal luminal diameter (HR 0.611, p=0.062) showed a tendency to reduce MB-ISR7.

Although there were no statistically significant differences in long-term outcomes between the whole BiOSS group and the whole rDES group, we think that there is still a place for BiOSS stents on cath lab shelves. BiOSS stents ensure easy access to the side branch, no problem with the choice of the proper strut for the SB and enable completing the procedure with provisional T-stenting (PTS) or any double-stent technique. Moreover, we think that BiOSS stents still provide an attractive alternative in coronary bifurcations with a pronounced diameter difference between the proximal and distal parts, minimising the risk of carina and plaque shift.

Limitations

The use of multiple stent types and drugs in the control group was a limitation, although this aspect of the design was intended to replicate real-world clinical practice. Finally, the differences in final kissing balloon and POT strategies between the study groups might also have affected the results.

Conclusions

There were no statistically significant differences in long-term (48 months) outcomes between the whole BiOSS group and the whole rDES group. The regression analysis showed that POT had the largest influence on lowering MACE and TLR rates in both groups.

Impact on daily practice

Similar results between the BiOSS Expert (stainless steel/paclitaxel; Balton) and BiOSS LIM (stainless steel/sirolimus; Balton) stents suggest that the stent design might play an important role, and therefore the new thin-strut version of the stent (cobalt-chromium platform) has been introduced onto the market – BiOSS LIM C (Balton).

Conflict of interest statement

R. Gil is a medical consultant for Balton. The other authors have no conflicts of interest to declare.

Supplementary data

To read the full content of this article, please download the PDF.


References

Volume 15 Number 16
Mar 20, 2020
Volume 15 Number 16
View full issue


Key metrics

On the same subject

10.4244/EIJV11I8A173 Dec 20, 2015
Coronary bifurcation treatment revisited
Lassen JF and Stankovic G
free

10.4244/EIJV16I16A231 Mar 19, 2021
Selection of stenting approach for coronary bifurcation lesions
Chen S
free

State-of-the-Art Review

10.4244/EIJ-D-21-01065 Jul 22, 2022
Percutaneous coronary intervention of bifurcation lesions
Hildick-Smith D et al
free
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved